Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.

Silva MVM, Ximenes RAA, Filho DBM, Martelli CMT, de Araújo TVB, Brickley E, Fontes JMSSA, Fulco GRN, Sá ACCL, Cordeiro MT, Castanha PMDS, Dos Santos Oliveira PA, Montarroyos UR. Kinetics of neutralizing and binding antibody responses following Zika virus infection during pregnancy: A nested analysis of participants from the microcephaly epidemic research group (MERG) and Zika in infants and pregnancy (ZIP) cohorts. Virus Res. 2026 Jun; 368:199725.

Zoref-Lorenz A, Allen CE, Behrens EM, Chandrakasan S, Chien M, Hermiston ML, Hinson AP, Intzes S, Isakoff MS, Leiding JW, Oladapo A, Panigrahi A, Patel SA, Pednekar P, Ray AK, Rothman JA, Saldaña BD, Walkovich KJ, Weinstein J, Yee JD, Jordan MB, Weinstein J, Hinson AP, Allen CE, Eckstein OS, Gulati N, Chandrakasan S, Haines H, Nakano TA, Patel SA, Behrens EM, Intzes S, Hays A, Saldaña BD, Jordan MB, Zoref-Lorenz A, Hanna R, Isakoff M, Ray AK, Rothman JA, Tandra A, Cooper R, Leiding JW, Chien M, Sarangi S, Gidvani-Diaz VK, Satwani P, Carter J, Henry M, Gloude N, Bhatt S, Bhatla D, Draper L, Panigrahi A, Hermiston ML, Modica R, Riskalla M, Baker A, Ward B. Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.

Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, Yin DE, Moye J, Spiegel H, Gama L, Gaudinski M, Capparelli EV. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. J Antimicrob Chemother. 2026 Jan 19; 81(2).

Muthuraman K, Jackman M, Liang Y, Garrett ME, Cui H, Nguyen LVH, Ivanochko D, Ye C, Pino PA, Hicks A, Maingot B, Yusko E, Benzeno S, Martínez-Sobrido L, Torrelles JB, Gilbert AE, Rubin BER, Keitany G, Jetha A, Julien J-P. Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions. J Virol. 2025 12 23; 99(12):e0152325.

Ho AWS, Fukuzawa T, Koga H, Ohmine K, Kawauchi H, Muraoka M, Ikuta Y, Gupta G, Okuda M, Onami I, Ayabe M, Takeiri A, Konishi H, Sugawara Y, Usami S, Ito E, Shibahara N, Ozeki K, Wada Y, Hirako A, Takahashi N, Sampei Z, Haraya K, Murao N, Fujii T, Torizawa T, Shimada H, Igawa T. Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function. EBioMedicine. 2025 Dec; 122:106009.

Yee DS, Davies JP, VanBlargan LA, Rahmberg AR, Burgomaster KE, Brooks K, Flynn JK, Shue B, Ortiz AM, Schaughency P, Best SM, Pierson TC, Brenchley JM. Oropouche virus efficiently replicates and is immunostimulatory in vivo in nonhuman primate species. Sci Adv. 2025 Sep 19; 11(38):eadx9405.

Guo Z, Ataran A, Ma P, Yu W, Hajirezaei H, Valenzuela Ripoll C, Pedersen LN, Rashidi O, Chan MM, Shen M, Kelley S, Sargazi A, Ozcan M, Lotfinaghsh A, Cho Y, Diab A, Grogan F, Klaas A, Pompian A, Imam A, Lodhi R, Zelleke AB, Kovacs A, Margulies KB, Szymanski J, Sardiello M, Razani B, Asnani A, Kopecky BJ, Signore PE, Yi BA, Basson CT, Ravichandran KS, Prabhu SD, Bergom C, Schilling JD, Lavine KJ, Javaheri A. Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. Circulation. 2025 Sep 09; 152(10):661-681.

Randolph T, Coleman H, Rauch AM, Hubert H, Witeof AE, Walker KD, Funke HH, Garcea RL. Superior immune responses from thermostable, single-administration rabies vaccines prepared using atomic layer deposition. J Pharm Sci. 2025 Sep; 114(9):103936.

Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin E, Duff MO, Seese A, Marini-Macouzet C, Ballweber-Fleming L, Lee WH, Cottrell CA, Liguori A, Georgeson E, Alavi N, Kubitz M, Phelps N, Seaton KE, Cohen KW, Anderson MA, Mondal K, Laufer DS, Kublin JG, Ward AB, Hyrien O, De Rosa SC, Himansu S, Leav B, Reuter C, Tomaras GD, Montefiori D, Walsh SR, Frank I, Sobieszczyk ME, Goepfert PA, Stephenson KE, Baden LR, Van Tieu H, Keefer MC, Clark J, Riddler SA, Schief WR, McElrath MJ. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci Transl Med. 2025 Jul 30; 17(809):eady6831.